Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 9, 2012, Pages 689-696

  Rasch, Magnus G ^a   Engsig, Frederik N ^a   Feldt Rasmussen, Bo ^b   Kirk, Ole ^a   Kronborg, Gitte ^a   Pedersen, Court ^c   Gerstoft, Jan ^a   Obel, Niels ^a  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atazanavir; Chronic kidney disease; HIV; Renal function; Tenofovir

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DENMARK; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84865322824     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.673730     Document Type: Article

References (33)

1. Crum N, Riffenburgh R, Wegner S, Agan B, Tasker S, Spooner K, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defi c Syndr 2006;41:194-200.
2. Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, Pedersen C, et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005;37:338-43. (Pubitemid 40691514)
3. Rling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006;42: 1488-95.
4. Herlitz L, Mohan S, Stokes M, Radhakrishnan J, D' Agati V, Markowitz G. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171-7.
5. Rodriguez-Nvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9:545-59.
6. Brewster U, Perazella M. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004;44:e81-4. (Pubitemid 39445931)
7. Eira M, Araujo M, Seguro AC. Urinary NO3 excretion and renal failure in indinavir-treated patients. Braz J Med Biol Res 2006;39:1065-70.
8. Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007;450:665-70. (Pubitemid 46986233)
9. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1. Ann Intern Med 2011;154:445-56.
10. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-8. (Pubitemid 351263473)
11. Kimmel P, Barisoni L, Kopp J. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003;139:214-26. (Pubitemid 38124604)
12. Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-54. (Pubitemid 46768608)
13. Hogg R, Furth S, Lemley K, Portman R, Schwartz G, Coresh J, et al. National Kidney Foundation ' s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416-21. (Pubitemid 36682280)
14. Miller WG, Myers G, Ashwood E, Killeen A, Wang E, Thienpont L, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005;129:297-304. (Pubitemid 40343981)
15. Rule A, Larson T, Bergstralh E, Slezak J, Jacobsen S, Cosio F. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-37.
16. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007;21:1119-27. (Pubitemid 46763282)
17. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-78.
18. Kalayjian R, Franceschini N, Gupta S, Szczech L, Mupere E, Bosch R, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008;22:481-7. (Pubitemid 351317289)
19. Christiansen JS. Glomerular hyperfiltration in diabetes mellitus. Diabet Med 1985;2:235-9. (Pubitemid 15246120)
20. Cherney DZ, Sochett E, Lai V, Dekker M, Slorach C, Scholey J, et al. Renal hyperfiltration and arterial stiffness in humans with uncomplicated type 1 diabetes. Diabetes Care 2010; 33:2068-70.
21. Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfi ltration. Acta Physiol (Oxf.) 2010;200:3-10.
22. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical signifi cance of hyperfiltration in diabetes. Diabetologia 2010;53:2093-104.
23. Perticone F, Maio R, Perticone M, Sciacqua A, Shehaj E, Naccarato P, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010;122:379-84.
24. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, De Santo NG. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int 2006;70:800-6. (Pubitemid 44215358)
25. Hanratty R, Chonchol M, Dickinson LM, Beaty B, Estacio R, Mackenzie T, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant 2010; 25:801-7.
26. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, et al. Changes in renal function associated with indinavir. AIDS 1998;12:F249-54. (Pubitemid 28558592)
27. Manosuthi W, Mankatitham W, Lueangniyomkul A, Prasithsirikul W, Tantanathip P, Suntisuklappon B, et al. Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens. AIDS Res Ther 2010;7:37.
28. Lucas G, Lau B, Atta M, Fine D, Keruly J, Moore R. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008;197:1548-57. (Pubitemid 351706485)
29. Izzedine H, M'Rad MB, Bardier A, Daudon M, Salmon D. Atazanavir crystal nephropathy. AIDS 2007;21: 2357-8.
30. Marroni M, Gaburri M, Mecozzi F, Baldelli F. Acute interstitial nephritis secondary to the administration of indinavir. Ann Pharmacother 1998;32:843-4. (Pubitemid 28341122)
31. Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1- infected patients. HIV Med 2011;12:620-31.
32. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265-72.
33. Jiang B, Hebert V, Zavecz J, Dugas T. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defi c Syndr 2006;42:391-5. (Pubitemid 44050884)